Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
commercialization and distribution in Europe of Capricor's lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy. Nippon Shinyaku has agreed to purchase about $15M of Capricor common stock at a 20% premium to the 60-day VWAP. Capricor will be responsible for the development and manufacturing of deramiocel for potential approval in all countries in the European Union, United Kingdom and several other countries in the region. Capricor will also receive an upfront payment of $20M subject to execution of the agreement and there are potential additional development and sales-based milestone payments to Capricor of up to $715M and Capricor will receive a double-digit share of product revenue. Recommended For You More Trending News Recommended For You More Trending News About CAPR Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $14.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $12.00 price target on the stock.MarketBeat
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewswire
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Sec Filings
- 9/17/24 - Form 8-K
- 8/23/24 - Form SC
- 8/23/24 - Form 3
- CAPR's page on the SEC website